ATL-001 (Achilles Therapeutics)

N/A

Report date: 2026/04/17 10:36:32

Base Information

Drug NameATL-001 (Achilles Therapeutics)

Drug Alias NamecNeT (Achilles Therapeutics)Neoantigen specific immunotherapies (Achilles Therapeutics)Clonal neoantigen T cell (Achilles Therapeutics)ATL-001

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Tumor Infiltrating Lymphocytes

Mechanisms of ActionT lymphocyte replacements

TargetsNot applicable

Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungMelanoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesGermanyUnited Kingdom +[5]

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesAchilles Therapeutics Ltd

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesAchilles Therapeutics Ltd

Active IndicationsN/A

Inactive IndicationsCarcinoma, Non-Small-Cell LungMelanoma

Other Information

ATC CodeN/A